Committee recommends study of pancreatic cancer vaccine continue
An independent committee has recommended that a clinical trial testing the experimental anticancer vaccine ELI-002 7P in people with pancreatic cancer should continue as…
News
Hemispherian gets FDA green-light for glioblastoma trial of GLIX1
The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in a Phase 1 clinical trial.
2 of 3 ovarian cancer patients in study respond to SON-1010 combo
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more patients — and soon, at…
Darzalex approved in EU to treat smoldering multiple myeloma
Johnson & Johnson‘s Darzalex (daratumumab) is now the first approved treatment for high-risk smoldering multiple myeloma (SMM) in the European Union (EU). SMM…
Scemblix now OK’d in Canada for treating newly diagnosed CML
More people in Canada with the rare blood cancer Ph+ CML — fully, Philadelphia chromosome-positive chronic myeloid leukemia — in the…
Early results ‘extremely positive’ for pancreatic cancer treatment combo
A clinical trial has revealed encouraging results for people with metastatic pancreatic cancer who received Ampligen (rintatolimod) alongside Imfinzi (durvalumab). Nearly two-thirds of…
Voranigo approval urged in EU for treatment of certain brain tumors
A committee of the European Medicines Agency (EMA) is recommending that the daily oral therapy Voranigo (vorasidenib) be approved in the European Union to treat…
Intervenn’s noninvasive ovarian cancer test to hit market this fall
A noninvasive diagnostic test to help distinguish ovarian cancer from benign pelvic masses will be available this fall. GlycoKnow Ovarian received a proprietary laboratory…
2 Blenrep combos for hard-to-treat myeloma approved for adults in EU
Two combination therapies using Blenrep (belantamab mafodotin) — designed to treat adults with relapsed or refractory multiple myeloma — have been approved in the…
Aucatzyl approved in Europe for relapsed/refractory B-ALL
The European Commission has approved Autolus Therapeutics’ cell therapy Aucatzyl (obecabtagene autoleucel) as a treatment for B-cell precursor acute lymphoblastic leukemia (B-ALL), an aggressive…
